A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
暂无分享，去创建一个
P. Galle | G. Giannelli | R. Kelley | E. Assenat | S. Faivre | E. Gane | A. Cleverly | P. Merle | J. Siebler | I. Gueorguieva | K. Benhadji | M. Lahn | Yumin Zhao | I. O. Hourmand | Y. Zhao | R. Kelley | PeterR. Galle | I. O. Hourmand